New obesity drug HDM1005 put to the test: will it play nice with other meds?
NCT ID NCT07502001
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study will test an experimental drug called HDM1005 in 42 overweight or obese adults. Researchers want to see how HDM1005 affects stomach emptying and whether it changes how the body processes common medications like metformin, atorvastatin, warfarin, and digoxin. Participants will receive HDM1005 injections along with single doses of these other drugs to measure safety and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HDM1005 injection
What this could lead to
If successful, this study could show that HDM1005 is safe to use alongside common medications like metformin and statins in people who are overweight or obese.
What could go wrong
This is a very early Phase 1 trial with only 42 people, so results may not apply to everyone. The study focuses on drug interactions, not weight loss or health outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••